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In Brief
Manteghi et al. demonstrate that HD-
PTP/PTPN23 is a haploinsufficient tumor
suppressor located on 3p21.3. They show
that Ptpn23+/ mice are predisposed to
spontaneous tumor formation and Myc-
induced lymphomagenesis via integrin-
dependent survival and invasion.
Importantly, they reveal that PTPN23
haploinsufficiency is common in human
cancers and correlates with poor survival.
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Endosomal sorting complexes required for transport
(ESCRT) drive cell surface receptor degradation re-
sulting in attenuation of oncogenic signaling and
pointing to a tumor suppressor function. Here, we
show that loss of function of an ESCRT protein
(HD-PTP encoded by the PTPN23 gene, located on
the tumor suppressor gene cluster 3p21.3) drives
tumorigenesis in vivo. Indeed, Ptpn23+/ loss predis-
poses mice to sporadic lung adenoma, B cell lym-
phoma, and promotes Myc-driven lymphoma onset,
dissemination, and aggressiveness. Ptpn23+/-
derived tumors exhibit an unaltered remaining allele
andmaintain 50% of HD-PTP expression. Consistent
with the role of HD-PTP in attenuation of integrin re-
cycling, cell migration, and invasion, hemizygous
Ptpn23+/ loss increases integrin b1-dependent B
cell lymphoma survival and dissemination. Finally,
we reveal frequent PTPN23 deletion and downregu-
lation in human tumors that correlates with poor sur-
vival. Altogether, we establish HD-PTP/PTPN23 as a
prominent haploinsufficient tumor suppressor gene
preventing tumor progression through control of in-
tegrin trafficking.INTRODUCTION
Cell surface receptors are key regulators of critical cellular pro-
cesses such as survival, proliferation, migration, and invasion.
Upon ligand stimulation, activated receptors are ubiquitinated,
internalized, and either sorted for degradation or recycled to
the cell surface. Misregulation of these processes results in
cell surface receptor stabilization and signaling persistence,
a well-recognized hallmark of cancer (Mellman and Yarden,
2013). The endosomal sorting complexes required for transport
(ESCRT) coordinate the sorting and degradation of cell surfaceCell
This is an open access article undreceptors and attenuate downstream signaling (Raiborg and
Stenmark, 2009). Therefore, ESCRT proteins were proposed to
act as tumor suppressor genes (TSGs) (Mattissek and Teis,
2014). Clinical evidence also supports this notion. For instance,
downregulation of the ESCRT member HCRP1 correlates with
reduced therapeutic efficacy of cetuximab in ovarian cancer
(Wittinger et al., 2011). However, due to the lack of viable homo-
zygous knockout mouse models, clear demonstration that
ESCRTs act as tumor suppressors has not been made yet.
The histidine domain containing protein tyrosine phosphatase
(HD-PTP) is a ubiquitously expressed pseudophosphatase
encoded by the PTPN23 gene (Gingras et al., 2009a, 2009b).
HD-PTP is also a key ESCRT-associated protein required for re-
ceptor degradation that was reported to inhibit migration and
invasion by preventing integrin, Src, and focal adhesion kinase
(FAK) signaling (Castiglioni et al., 2007; Kharitidi et al., 2015;
Lin et al., 2011; Mariotti et al., 2009). We hypothesized that
PTPN23 might be a haploinsufficient TSG since it maps to
3p21.3, a prevalent TSG cluster frequently hemizygously deleted
in many human tumors, but rarely mutated on the remaining
allele (Angeloni 2007; Ji et al., 2005). In accord, PTPN23 TSG
function was suggested since HD-PTP overexpression delays
xenograft growth of testicular germ cell tumors (Tanaka et al.,
2013). However, the HD-PTP/PTPN23 TSG function and mech-
anism has not been yet demonstrated in vivo by loss-of-function
studies. Therefore, we decided to directly investigate the tumor
predisposition of Ptpn23 hemizygous knockout mice (Gingras
et al., 2009a).RESULTS
Ptpn23+/ Mice Are Predisposed to B Cell Lymphoma
and Lung Adenoma
To investigate the in vivo functions of HD-PTP/PTPN23, C57BL/6;
129/OlaHsd F1 Ptpn23
+/mice were backcrossed into C57BL/6
or 129/OlaHsd backgrounds (Gingras et al., 2009a). As we re-
ported, Ptpn23/ deletion was embryonic lethal (Gingras
et al., 2009a), while Ptpn23+/ animals were born at the expected
Mendelian frequency, developed normally, and were fertile.Reports 15, 1893–1900, May 31, 2016 ª 2016 The Author(s). 1893
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 1. Ptpn23+/ Mice Are Predisposed
to Spontaneous Tumor Formation
(A) Representative images of the indicated
Ptpn23+/ tumors.
(B) Percent tumor incidence in the indicated
strains: mesenteric lymphomas (16–18 months;
Ptpn23+/: 12/23 versus Ptpn23+/+: 3/24) and lung
adenomas (15–18 months; Ptpn23+/: 15/59
versus Ptpn23+/+: 2/50).
(C) Western blot analysis of HD-PTP levels in the
indicated normal tissues. Actin was used as a
loading control.
(D and E) Immunohistochemical analyses of the
Ptpn23+/ mesenteric lymphoma (D) and lung
adenoma (E) performed with the indicated anti-
bodies. Insets indicate magnified areas and
dashed lines delimit the tumor edge.
(F and G) Genomic qPCR quantification of the
Ptpn23 allele number in normal (N) and tumor (T)
tissues isolated from lymph nodes (n = 5) (F) and
lung (n = 2) (G).
(H) Western blot analysis of HD-PTP levels in
normal (N) and tumor (T) lymph node tissues of the
indicated genotypes. Actin was used as a loading
control. Data are expressed as mean ± SEM.
See also Figure S1.Interestingly, by 72 weeks of age, Ptpn23+/ mice developed
spontaneous mesenteric lymphoma (C57BL/6) and lung ade-
noma (129/OlaHsd), with a 4- to 5-fold increased incidence
compared to Ptpn23+/+ littermates (Figures 1A and 1B). Consis-
tent with hemizygous Ptpn23 deletion, a 50% reduction in
HD-PTP expression was detected (Figures 1C, S1A, and S1B),
suggesting that the remaining allele does not transcriptionally
compensate the allele loss. Immunohistochemistry analysis of
mesenteric lymph node tumors using B cell (B220)- and T cell
(CD3)-specific markers confirmed a lymphoma of B cell origin
(Figure 1D). Similarly, staining of lung tumors with lung cell line-
age markers (Clara cells: CCSP and type II pneumocytes: SPC)1894 Cell Reports 15, 1893–1900, May 31, 2016confirmed a benign adenoma phenotype
originated from type II pneumocytes (Fig-
ure 1E). Together, these data indicate
that both tumor types were of primary
origin.
Genomic qPCR, exon sequencing, and
western blot analysis ofPtpn23+/ tumors
revealed that the remaining wild-type
Ptpn23 allele was unaltered in terms of
sequence and expression levels (Figures
1F–1H and S1C). Thus, the inactivation
of the remaining Ptpn23 allele is not
required for tumorigenesis, implying a
haploinsufficient tumor suppressor
function.
To examine Ptpn23 TSG mechanism,
we employed mouse embryonic fibro-
blasts (MEFs) isolated from Ptpn23+/+
and Ptpn23+/ mice. While Ptpn23+/
loss did not affect cell proliferation, itpromoted focus formation and loss of contact inhibition in
immortalized MEFs (Figures S1D–S1G). To address Ptpn23
function in oncogene-driven cell transformation, primary and
immortalized MEFs were transduced with retrovirally delivered
H-RasV12 oncogene. The Ptpn23 status did not influence
H-RasV12-induced growth arrest in primary MEFs (Figure S1H)
or H-RasV12-mediated soft agar growth in immortalized MEFs
(Figure S1I). However, H-RasV12 significantly increased the
Ptpn23+/ proliferation rate of immortalized MEFs (Figure S1J).
Altogether, our results demonstrate that Ptpn23+/ contributes
to cell transformation following immortalization and/or oncogene
expression.
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Figure 2. Ptpn23 Hemizygosity Accelerates
Myc-Driven Lymphomagenesis
(A) Representative PCR-based DNA genotyping
performed using primers specific for the Ptpn23
wild-type (WT) or mutated (truncated/b-geo) allele
and the Em-myc transgene.
(B) Representative western blot analysis of HD-
PTP levels in bonemarrow-derived B cells. Actin is
shown as loading control.
(C and D) Kaplan-Meier analysis of tumor onset (C)
and overall survival (D) in the indicated strains. The
median onset and survival are indicated.
(E) Average spleen weight of the indicated strains
(70 days).
(F) Genomic qPCR quantification of the Ptpn23
allele number in normal (N) and tumor (T) lymph
node tissues.
(G) Relative Ptpn23 mRNA levels quantified by
qRT-PCR in the indicated lymphoma samples.
(H) Representative western blot analysis of the
HD-PTP protein levels in the indicated lymph
node tumors (LNT). Tubulin is shown as a loading
control. Data are expressed as mean ± SEM.
See also Figure S2.Ptpn23 Hemizygosity Accelerates Myc-Driven
Lymphomagenesis
To determine if Ptpn23+/ predisposes to oncogene-driven lym-
phomagenesis in vivo, Ptpn23+/ mice were crossed with the
transgenic Em-myc B cell lymphoma mouse model (Figure 2A)
(Adams et al., 1985). Reduced HD-PTP expression was
confirmed in Ptpn23+/ Em-myc B cells (Figures 2B and S2A).
Interestingly, the lymphoma onset of Ptpn23+/ Em-myc mice
was accelerated compared to Ptpn23+/+ Em-myc (43 versus
87 days) and correlated with reduced survival (73 versusCell R125 days) (Figures 2C and 2D). Pathology
analysis confirmed a lymphoblastic lym-
phoma phenotype, accompanied by
advanced splenomegaly in Ptpn23+/
Em-myc animals (Figure 2E). An intact
Ptpn23 wild-type allele was preserved
and expressed in Ptpn23+/ Em-myc lym-
phoma when compared to Em-myc
tumors (Figures 2F–2H and S2B). Alto-
gether, our data confirmed that Ptpn23
acts as a haploinsufficient TSG in vivo in
a Myc-driven lymphomagenesis mouse
model.
The p53-ARF axis is crucial for lym-
phoma development, and its loss pro-
motes Myc-induced lymphomagenesis
(Eischen et al., 1999). While p53 ex-
pression and integrity (assessed by
sequencing and western blot) were unal-
tered in Ptpn23+/ Em-myc lymph nodes
tumors, ARF protein levels were signifi-
cantly decreased (Figure S2C). Consis-
tently, ARF expression was reduced in
spleen and MEFs from Ptpn23+/ mice
(Figures S2D and S2E), which resulted from decreased tran-
scriptional activity, as lower Arf mRNA levels and decreased
Arf promoter activity were observed in Ptpn23+/MEFs (Figures
S2F and S2G). HD-PTP knockdown in wild-type MEFs similarly
reduced ARF protein levels, confirming that HD-PTP regulates
ARF expression (Figure S2H). Commonly, ARF deletion leads
to bypass of replicative senescence and spontaneous immortal-
ization of primary MEFs cultured in standard conditions (Kamijo
et al., 1997). Consistent with a partial ARF reduction, the
Ptpn23+/ MEFs did not bypass senescence (Figure S2I), buteports 15, 1893–1900, May 31, 2016 1895
their immortalization rate was accelerated (Figures S2I and S2J).
Our results suggest that hemizygous loss of Ptpn23 might pro-
mote tumorigenesis by reducing ARF levels and enhancing
immortalization rate. However, the specific mechanism involved
remains elusive.
Ptpn23 Hemizygous Loss Promotes Integrin-Dependent
B Cell Lymphoma Survival and Spreading
Overcoming Myc-induced apoptosis is a prerequisite for Myc-
driven lymphomagenesis (Eischen et al., 1999). Consistent with
the accelerated lymphomagenesis, TUNEL staining indicated
reduced cell death levels in Ptpn23+/ Em-myc compared to
Em-myc tumors (Figures 3A and S3A). In parallel, cell viability of
freshly isolated Ptpn23+/ Em-myc lymph node tumors (LNT)
and bone marrow-derived cells was increased (Figures 3B and
3C). We recently reported that loss of HD-PTP stimulates b1 in-
tegrin cell surface stabilization, turnover, and promotes FAK
downstream signaling (Kharitidi et al., 2015), both involved in
cell survival and tumorigenesis in different cancers, including
lymphoma (Alanko et al., 2015; Bosch et al., 2011; Desgrosellier
and Cheresh, 2010). Consistent with our previous work,
Ptpn23+/ Em-myc B cells exhibited elevated cell surface integrin
levels (Figures 3D and S3B). Moreover, increased total integrin
and FAK phosphorylation levels (pFAK) were observed in
Ptpn23+/ Em-myc tumors (Figure 3E) as well as in Em-myc tu-
mor-derived B cells downregulated for HD-PTP expression
(Figure 3F). In agreement with integrin-dependent downstream
signaling, treatment of the Em-myc B cells with an integrin
b1-blocking antibody reduced pFAK levels to the control levels
(Figure 3G). Furthermore, HD-PTP downregulation in Em-myc B
cells conferred a survival advantage upon serum starvation
(FBS), which is abolished by FAK inhibitor (PND-1186) or integ-
rin b1-blocking antibody (Figures 3G, 3H, and S3C). Thus, our
data reveal that loss of HD-PTP enhances cell survival by
increasing integrin b1 and pFAK levels.
Our previous work indicated that HD-PTP depletion favors in-
tegrin-dependent cell migration and invasion, known as drivers
of tumor progression and metastasis in various cancers,
including lymphoma (Dozynkiewicz et al., 2012; Kharitidi et al.,
2015; Stroeken et al., 1998, 2000). To determine if a potentiated
pro-invasive phenotype contributes to PTPN23 TSG function,
we used MEFs and confirmed that Ptpn23+/ MEFs exhibited
increased integrin b1 and pFAK levels and integrin-dependent
invasion rate (Figures 3I and 3J). Consistently, we observed a
higher incidence of Em-myc lymphoma dissemination in multiple
tissues upon Ptpn23+/ loss (Figures 3K and S3D). Altogether,
our data imply that hemizygous loss of Ptpn23 stimulates tumor-
igenesis by promoting integrin-dependent cell survival and
invasion.
Loss of PTPN23 Is Frequent in Human Cancer
In agreement with a PTPN23 haploinsufficient TSG function,
extensive bioinformatic analyses using public cancer databases
revealed frequent PTPN23 hemizygous deletions, mutations
(Figures 4A and S4A), and reduced HD-PTP expression (Fig-
ure 4B) in different human cancers. In addition, PTPN23 mRNA
levels were significantly reduced in human lymphoma (Figure 4C)
and lung cancer (Figure 4D), when compared to normal tissue.1896 Cell Reports 15, 1893–1900, May 31, 2016Finally, PTPN23 mRNA downregulation in lung and breast can-
cer (Figures 4E and 4F) and loss of PTPN23 allele number in
breast cancer (Figure S4B) correlate with reduced survival.
Different PTPN23 point mutations were reported in human
cancers (Figure S4A), including lymphoma (Schmitz et al.,
2012; Cerami et al., 2012; Gao et al., 2013). The effect of
some of these missense mutations on HD-PTP expression and
stability were addressed via their ectopic expression in HeLa
cells followed by cycloheximide chase. Interestingly, two
missensemutations identified in lymphoma significantly destabi-
lized HD-PTP protein (Figures S4C and S4D), implying that these
mutations contribute to PTPN23 loss of function. Altogether, our
data revealed that PTPN23 acts as a prominent haploinsufficient
TSG in humans.
DISCUSSION
While the TSG function of HD-PTP was previously proposed by
Tanaka et al. (2013) based on HD-PTP overexpression studies,
the evidence that PTPN23 loss of function drives oncogenic
transformation, in vitro and in vivo, was lacking. Taking advan-
tage of our Ptpn23+/ mouse model, here, we establish
PTPN23 as a haploinsufficient TSG in vivo. Indeed, we demon-
strate that Ptpn23+/ deficiency predisposes mice to sporadic
B cell lymphoma, lung tumors, and accelerated Myc-driven lym-
phomagenesis. Moreover, extensive bioinformatic analyses
reveal recurrent hemizygous PTPN23 loss in many human tu-
mors, which correlates with poor outcome. Consistently, hemi-
zygous deletions in the 3p21.3 region are very frequent in human
tumors and were described as the earliest genetic alteration in
several types of lung cancer (Hung et al., 1995; Wistuba et al.,
1999) while mutations are infrequent (Lerman and Minna,
2000). PTPN23 mutation rate is low across human tumors
(<7%) (cBioPortal), however, some mutations were reported in
human cancers. Interestingly, by revealing the destabilizing na-
ture of some of these mutations, our data suggest an alternative
loss of function mechanism for HD-PTP.
Importantly, this study presents evidences linking ESCRT and
TSG function. Indeed, despite the essential role of ESCRT com-
ponents in cell surface receptor degradation leading to down-
stream signaling termination, their TSG function was not clearly
established, since their homozygous deletion lead to embryonic
lethality in mice. Here, we report that loss of one Ptpn23 allele is
sufficient to drive tumorigenesis in vivo in mice but also in hu-
mans. Based on this data, we hypothesize that other ESCRT pro-
teins might also acts as haploinsufficient TSGs. We previously
reported that HD-PTP depletion accelerates integrin recycling
and boosts integrin-dependent cell migration and invasion
(Kharitidi et al., 2015). Interestingly, potentiated integrin recycling
and signaling were reported as drivers of tumorigenesis by
enhancing cell survival, invasion, and metastasis formation
in vivo (Caswell et al., 2008; Delamarre et al., 2009; Dozynkiewicz
et al., 2012). In agreement, we report here that Ptpn23 TSG
mechanism is related to integrin-dependent pro-survival and
pro-invasive properties in vitro and in vivo, which contributes
to tumor initiation, progression, and dissemination. Moreover,
we demonstrate using a knockout animal that integrin trafficking
controls tumor progression in vivo.
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Figure 3. Ptpn23+/ Loss Promotes Integrin-Depen-
dent Survival and Invasion
(A) Quantification of TUNEL positive cells in the indicated
lymph node tumors (LNT).
(B and C) Percent cell viability determined by trypan blue
exclusion in freshly isolated LNT (B) or bone marrow-derived
B cells (6-week-old mice) and cultured 48 hr in vitro (C).
(D) Flow cytometry quantification of the cell surface integrin
b1 levels in B cells (B220+ gated population) derived from
LNT (8-week-old mice).
(E–G) Representativewestern blot analysis of primary LNT (E)
and Em-myc B cells depleted (sh-HD) or not (sh-SCR) for
HD-PTP expression (F and G), treated or not with integrin
b1-blocking antibody (5 mg/ml) for 18 hr when indicated (G).
(H) Fold viability measured in the indicated B cells, pretreated
with DMSO, PND-1186, IgM, or integrin b1-blocking anti-
body for 18 hr and serum-starved (FBS) for 5 hr. Data
represent the mean ± SEM of greater than or equal to five
independent experiments.
(I) Representative western blot analysis of MEFs plated on
fibronectin.
(J) Fold cell invasion of MEFs, treated with integrin
b1-blocking or control (IgM) antibodies assessed by
xCELLigence technology.
(K) Incidence of lymphoma dissemination in the indicated
strains. Data represent the mean ± SEM of greater than or
equal to three independent experiments.
See also Figure S3.
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Figure 4. PTPN23 Loss of Function Is Frequent in Human Cancers
(A) Frequency of PTPN23 hemizygous deletions in human cancers (cBioPortal).
(B) Percent human tumor samples downregulated for HD-PTP over total samples (Protein Atlas).
(C) Relative PTPN23 mRNA levels quantified by qRT-PCR in cDNA tissue scan array (33 lymphoma and 5 normal lymph node samples; Origene), normalized to
actin transcript levels and expressed as the log rank ratio of PTPN23 expression in lymphoma samples compared to normal lymph nodes. The horizontal lines
represents SEM.
(D) PTPN23 mRNA levels in human lung normal and tumor samples. Data are expressed as mean ± SEM (p = 0.002).
(E and F) Kaplan-Meier analysis of lung (E) and breast cancer patient survival (F) according toPTPN23mRNA levels classified as low or high PTPN23mRNA levels.
See also Figure S4.In addition, we observed that HD-PTP depletion correlates
with reduced ARF levels via an unknown mechanism currently
under investigation. The INK4a/ARF locus is frequently silenced
or deleted in human cancers and has been described as amech-1898 Cell Reports 15, 1893–1900, May 31, 2016anism to bypass oncogene-induced apoptosis and senescence
(Kamijo et al., 1997; Ruas and Peters, 1998). In agreement,
decreased apoptosis levels in Ptpn23+/ tumors and increased
rate of immortalization in Ptpn23+/ MEFs were observed.
However, our data suggest that hemizygous loss ofPtpn23 is not
sufficient to fully transform cells and that other genetic alter-
ations are required.
Altogether, it is likely that PTPN23 hemizygous loss affects
multiple signaling cascades including integrin and ARF that
together potentiate tumor initiation and progression in vivo.
Therefore, identification of additional signaling receptors or
pathways targeted by HD-PTP will be the subject of future
investigations.EXPERIMENTAL PROCEDURES
For additional experimental procedures see the Supplemental Experimental
Procedures.
Animal Studies
Experimental procedures were approved by the animal care committee of
McGill University and performed according the committee rules and regula-
tions. The Ptpn23 mouse model was described (Gingras et al., 2009a).
Ptpn23+/ mice were backcrossed to C57BL/6 or 129/OlaHsd backgrounds
over eight generations and the Em-myc offspring were obtained by crossing
C57BL/6 Ptpn23+/ (N10) with C57BL/6 Em-myc mice (gift from R. Jones,
McGill University). Mice were genotyped twice (weaning and sacrifice), using
primers listed in Table S1. Mice were sacrificed at specific time points (3, 6,
8, 10, 12, 16, 18, and 20 months) and lung or lymphoma tumors were moni-
tored upon dissection. The onset of lymphomagenesis in Em-myc mice was
monitored bi-weekly by palpation and mice were sacrificed upon any sign of
distress. Tissues were collected, snap-frozen in liquid nitrogen for DNA,
RNA, and protein extraction or fixed in 10% neutral-buffered formalin for his-
tological analysis.
Cell-Based Assays
Cell viability was determined by Trypan blue exclusion method or using Cell-
Titer-Glo (Promega: G755B) according to manufacturer’s instructions. Briefly,
1.5 3 104 B cells were seeded in 12-well plate and treated with 1 mM FAK in-
hibitor (PND-1186, Selleck Chemicals: 7653), DMSO, or 5 mg/ml IgM (Bio-
legend: 401002) or integrin b1-blocking antibody (BD: 555003) for 18 hr.
Then cells were resuspended in FBS-free media supplemented with either
DMSO, PND-1186, IgM, or integrin b1-blocking antibody, and 1 3 104 cells
were seeded in 96-well plate and incubated 5 hr at 37C. Following Cell-
Titer-Glo addition, luminescence was measured using a PHERAstar FS HTS
microplate reader and cell viability was expressed as the fold of control. Inva-
sion assays were performed as described (Kharitidi et al., 2015). Briefly, 2 3
104 MEFs cells, treated with IgM control or integrin b1-blocking antibody,
were employed in triplicate in Matrigel invasion assays, using xCELLigence
technology. Data were expressed as the fold invasion rate (cell index/hr) calcu-
lated for a 5-hr interval.
Human Data Analysis
TCGA data including lung cancer gene expression RNA sequencing (RNA-seq)
(Illumina HiSeq: 1,124 samples), breast invasive carcinoma copy number (gis-
tic2-thresholded: 1,079 samples with survival data) were downloaded from
cancer genomics browser website (https://genome-cancer.ucsc.edu/proj/
site/hgHeatmap/). Kaplan-Meier curves for the analysis of PTPN23 copy num-
ber were generated using diploid or haploid samples. Overall survival analysis
of lung cancer patients using PTPN23 mRNA levels (probe 223150_s_at and
split patients by auto select best cutoff option) and relapse free survival anal-
ysis of breast cancer patients (probe 223150_s_at and split patients by me-
dian) were extracted from online KM-Plotter database and graphed with
SPSS software (Gyo¨rffy et al., 2010; Gy}orffy et al., 2013). Data on hemizygous
deletion of PTPN23 and mutations in cancers were extracted from the cBio-
Portal public database. Protein expression data were extracted from the Hu-
man Protein Atlas database (ENSG0000076201-PTPN23/cancer), and the
relative incidence of HD-PTP downregulation was obtained by comparingthe intensity of staining in tumor samples (graded as high medium, low, or un-
detectable) to normal tissue (Table S2).SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2016.04.076.
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